What is the optimal treatment strategy to maximize long-term survival for a 55-year-old white male with newly diagnosed multiple myeloma?

Optimal Treatment Strategy for Long-Term Survival in Newly Diagnosed Multiple Myeloma

For a 55-year-old white male with newly diagnosed multiple myeloma, the optimal treatment strategy to maximize long-term survival is induction therapy with a daratumumab-containing quadruplet regimen (such as daratumumab/bortezomib/lenalidomide/dexamethasone or daratumumab/bortezomib/thalidomide/dexamethasone), followed by autologous stem cell transplantation (ASCT), and then lenalidomide maintenance therapy. 1, 2

Risk Stratification First

Before initiating treatment, perform cytogenetic risk stratification using FISH to identify high-risk features including t(4;14), t(14;16), del(17p), and assess International Staging System (ISS) stage 3. This determines treatment intensity and guides post-transplant strategies, though it does not change the fundamental approach of quadruplet induction followed by ASCT in this transplant-eligible patient.

Induction Therapy: Quadruplet Regimens Are Now Standard

The treatment landscape shifted dramatically in 2025 with quadruplet regimens becoming the standard of care for transplant-eligible patients 2, 4. The most recent NCCN Guidelines (Version 1.2025) emphasize daratumumab-containing quadruplet regimens as preferred options 2.

Preferred Quadruplet Options:

• Daratumumab/bortezomib/lenalidomide/dexamethasone (Dara-RVD) - This represents the optimal choice based on the principle that using the most effective treatment in first-line optimizes outcomes 5

• Daratumumab/bortezomib/thalidomide/dexamethasone (Dara-VTD) - The CASSIOPEIA trial demonstrated deeper response rates (39% vs 26% CR or better at day 100 post-transplant) when daratumumab was added to VTD 1

Why Quadruplet Over Triplet?

While triplet regimens like bortezomib/lenalidomide/dexamethasone (RVD) were previously standard and showed superior outcomes in the S0777 trial (median OS 75 months, median PFS 43 months) 6, the addition of daratumumab in first-line has consistently demonstrated:

• Deeper responses with higher complete remission rates
• Improved progression-free survival
• Higher rates of minimal residual disease (MRD) negativity, which is now recognized as a surrogate marker for survival 4

Treatment sequences beginning with daratumumab-containing regimens in first-line optimize clinical outcomes compared with alternative sequences 5.

Autologous Stem Cell Transplantation Remains Essential

At age 55, this patient is clearly transplant-eligible. ASCT after induction remains the standard of care and is associated with superior long-term outcomes 3, 6.

The IFM/DFCI 2009 trial definitively showed that incorporating early ASCT:

• Improved complete remission rates (59% vs 49%)
• Increased MRD-negativity rates (80% vs 65%)
• Extended median PFS (43 vs 34 months, HR 0.69, P<0.001) 6

Perform ASCT after 3-4 cycles of induction therapy 7, 8. High-dose melphalan 200 mg/m² is the standard conditioning regimen 7.

Critical Timing Point:

Collect stem cells after achieving at least partial response but before excessive therapy that might impair collection 9. Modern quadruplet regimens do not adversely affect stem cell mobilization when used appropriately.

Maintenance Therapy: Lenalidomide is Category 1

After ASCT, initiate lenalidomide maintenance therapy - this is a Category 1 recommendation 2.

Lenalidomide maintenance:

• Increases progression-free survival (Level 1A evidence) 3
• Possibly improves overall survival (Level 2B evidence) 3
• Should be continued until disease progression or unacceptable toxicity

Typical dosing: Lenalidomide 10-15 mg daily continuously 8. The patient in the case example from the guidelines maintained sustained complete remission on lenalidomide 10 mg/day for 3 years post-ASCT 8.

Alternative Maintenance Options:

If lenalidomide is not tolerated:

• Daratumumab/lenalidomide combination
• Carfilzomib/lenalidomide combination
• Bortezomib ± lenalidomide 2

Treatment Algorithm Summary

For this 55-year-old transplant-eligible patient:

1. Induction (3-4 cycles): Daratumumab/bortezomib/lenalidomide/dexamethasone (preferred) or Daratumumab/bortezomib/thalidomide/dexamethasone

2. Stem cell collection: After achieving ≥PR

3. High-dose therapy: Melphalan 200 mg/m² followed by ASCT

4. Maintenance: Lenalidomide 10-15 mg daily continuously until progression

5. Monitoring: Serial assessment for MRD negativity, which predicts superior outcomes 4

Critical Pitfalls to Avoid

Do not use triplet regimens when quadruplet regimens are available - The evidence clearly shows that starting with the most effective treatment (daratumumab-containing quadruplets) in first-line maximizes long-term outcomes 5.

Do not delay or omit ASCT in this young, fit patient - Despite the "cure versus control" debate, ASCT provides superior PFS and higher MRD-negativity rates, which correlate with improved survival 6, 4.

Do not skip maintenance therapy - Lenalidomide maintenance is supported by Level 1A evidence for improving PFS and should be standard 3, 2.

Monitor for second primary malignancies - There is a low but real incidence with lenalidomide maintenance, requiring vigilant surveillance 6.

High-Risk Disease Considerations

If cytogenetics reveal high-risk features (del 17p, t(4;14), t(14;16)):

• The same quadruplet induction approach applies
• Consider extended maintenance with bortezomib-containing regimens 9
• More intensive monitoring for early relapse
• Potential consideration of tandem transplant or novel consolidation strategies in clinical trials 1

The fundamental strategy remains unchanged: aggressive upfront therapy with quadruplet induction, ASCT consolidation, and prolonged maintenance offers the best chance for long-term survival and potential cure 8, 4.